Prevention of Depression in Patients with Cancer: A Systematic Review
DOI:
https://doi.org/10.61841/as8k2g23Keywords:
Anxiety, Antidepressant, Cancer, Depression, PreventiveAbstract
Depression and depressive symptoms are prevalent in patients with cancer. Depression is under- diagnosed and therefore the patients often receive inadequate treatment for their depression. The aim of this study was to identify ways to prevent depression in patients with cancer. This systematic review used the Preferred Reporting Items for Systematic Review (PRISMA) approach. Databases were used to identify suitable articles from Scopus, PubMed, Science Direct and Proquest. The articles were limited to being published between 2009 and 2020, written in English and full-text articles. The literature review used the keywords “anxiety, antidepressant, cancer, depression and preventive.” When searching the articles, “AND” was also used. The inclusion criteria in the search strategy consisted of: 1) adult humans ≥18 years of age diagnosed with cancer; 2) undergoing antidepressive treatment of any kind; 3) depression and/or depressive symptoms and 4) the study design was a randomized controlled trial. Studies were excluded if the studies had less than 30 samples as this means that they do not have enough strength to use to detect a significant relationship. Following this screening, 15 articles met the inclusion criteria. The studies were classified into 3 groups based on the type of intervention used. The interventions were pharmacotherapy, psychotherapy and other interventions such as exercise programs. Depression in patients with cancer can be prevented. Preventive treatment should start before or during the oncological treatment. Treating psychiatric conditions in patients with cancer may improve not only their quality of life and prognosis but also their survival.
Downloads
References
[1] D. Chisholm et al., “Scaling-up treatment of depression and anxiety: A global return on investment analysis,”
The Lancet Psychiatry, vol. 3, no. 5, pp. 415–424, 2016.
[2] S. L. Hart et al., “Meta-analysis of efficacy of interventions for elevated depressive symptoms in adults diagnosed with cancer,” J. Natl. Cancer Inst., vol. 104, no. 13, pp. 990–1004, 2012.
[3] T. Okuyama, T. Akechi, L. Mackenzie, and T. A. Furukawa, “Psychotherapy for depression among advanced, incurable cancer patients: A systematic review and meta-analysis,” Cancer Treat. Rev., vol. 56, pp. 16–27, 2017.
[4] G. Ostuzzi, F. Matcham, S. Dauchy, C. Barbui, and M. Hotopf, “Antidepressants for the treatment of depression in people with cancer ( Review ) SUMMARY OF FINDINGS FOR THE MAIN COMPARISON,” no. 6, 2016.
[5] J. Walker et al., “Prevalence of depression in adults with cancer: A systematic review,” Ann. Oncol., vol. 24, no. 4, pp. 895–900, 2013.
[6] S. W. M. C. Maass, C. Roorda, A. J. Berendsen, P. F. M. Verhaak, and G. H. De Bock, “The prevalence of long-term symptoms of depression and anxiety after breast cancer treatment: A systematic review,” Maturitas, vol. 82, no. 1, pp. 100–108, 2015.
[7] A. M. H. Krebber et al., “Prevalence of depression in cancer patients: A meta-analysis of diagnostic interviews and self-report instruments,” Psychooncology., vol. 23, no. 2, pp. 121–130, 2014.
[8] N. P. Suppli et al., “Survival after early-stage breast cancer of women previously treated for depression: A nationwide Danish cohort study,” J. Clin. Oncol., vol. 35, no. 3, pp. 334–342, 2017.
[9] Ó. Arrieta et al., “Association of depression and anxiety on quality of life, treatment adherence, and prognosis
in patients with advanced non-small cell lung cancer,” Ann. Surg. Oncol., vol. 20, no. 6, pp. 1941–1948, 2013.
[10] C. M. H. Chan, W. A. Wan Ahmad, M. Md Yusof, G. F. Ho, and E. Krupat, “Effects of depression and anxiety on mortality in a mixed cancer group: A longitudinal approach using standardised diagnostic interviews,” Psychooncology., vol. 24, no. 6, pp. 718–725, 2015.
[11] K. Zhou et al., “A clinical randomized controlled trial of music therapy and progressive muscle relaxation training in female breast cancer patients after radical mastectomy: Results on depression, anxiety and length of hospital stay,” Eur. J. Oncol. Nurs., vol. 19, no. 1, pp. 54–59, 2015.
[12] N. Travier et al., “Effects of an 18-week exercise programme started early during breast cancer treatment: A randomised controlled trial,” BMC Med., vol. 13, no. 1, pp. 1–11, 2015.
[13] A. Mehnert, S. Veers, D. Howaldt, K. M. Braumann, U. Koch, and K. H. Schulz, “Effects of a physical exercise rehabilitation group program on anxiety, depression, body image, and health-related quality of life among breast cancer patients,” Onkologie, vol. 34, no. 5, pp. 248–253, 2011.
[14] Y. H. Kim, H. J. Kim, S. Do Ahn, Y. J. Seo, and S. H. Kim, “Effects of meditation on anxiety, depression, fatigue, and quality of life of women undergoing radiation therapy for breast cancer,” Complement. Ther. Med., vol. 21, no. 4, pp. 379–387, 2013.
[15] M. V. Hansen et al., “Effect of melatonin on depressive symptoms and anxiety in patients undergoing breast cancer surgery: A randomized, double-blind, placebo-controlled trial,” Breast Cancer Res. Treat., vol. 145, no. 3, pp. 683–695, 2014.
[16] J. Nangia et al., “Effect of a scalp cooling device on alopecia inwomen undergoing chemotherapy for breast cancer: The SCALP randomized clinical trial,” JAMA - J. Am. Med. Assoc., vol. 317, no. 6, pp. 596–605, 2017.
[17] D. R. Hopko et al., “Brief behavioral activation and problem-solving therapy for depressed breast cancer patients: Randomized trial,” J. Consult. Clin. Psychol., vol. 79, no. 6, pp. 834–849, 2011.
[18] C. Fernández-Rodríguez, E. Villoria-Fernández, P. Fernández-García, S. González-Fernández, and M. Pérez- Álvarez, “Effects of Behavioral Activation on the Quality of Life and Emotional State of Lung Cancer and Breast Cancer Patients During Chemotherapy Treatment,” Behav. Modif., vol. 43, no. 2, pp. 151–180, 2019.
[19] J. K. Van Vulpen et al., “Effects of an exercise program in colon cancer patients undergoing chemotherapy,”
Med. Sci. Sports Exerc., vol. 48, no. 5, pp. 767–775, 2016.
[20] C. Pitceathly, P. Maguire, I. Fletcher, M. Parle, B. Tomenson, and F. Creed, “Can a brief psychological intervention prevent anxiety or depressive disorders in cancer patients? A randomised controlled trial,” Ann. Oncol., vol. 20, no. 5, pp. 928–934, 2009.
[21] W. M. Lydiatt, D. Bessette, K. K. Schmid, H. Sayles, and W. J. Burke, “Prevention of depression with escitalopram in patients undergoing treatment for head and neck cancer: Randomized, double-blind, placebo- controlled clinical trial,” JAMA Otolaryngol. - Head Neck Surg., vol. 139, no. 7, pp. 678–686, 2013.
[22] M. Alamdarsaravi et al., “Efficacy and safety of celecoxib monotherapy for mild to moderate depression in patients with colorectal cancer: A randomized double-blind, placebo controlled trial,” Psychiatry Res., vol. 255, pp. 59–65, 2017.
[23] S. Park et al., “Mindfulness-Based Cognitive Therapy for Psychological Distress, Fear of Cancer Recurrence, Fatigue, Spiritual Well-Being, and Quality of Life in Patients With Breast Cancer—A Randomized Controlled Trial,” J. Pain Symptom Manage., 2020.
[24] P. H. Wu, S. W. Chen, W. T. Huang, S. C. Chang, and M. C. Hsu, “Effects of a Psychoeducational Intervention in Patients with Breast Cancer Undergoing Chemotherapy,” J. Nurs. Res., vol. 26, no. 4, pp. 266–279, 2018.
[25] Y. H. Kim, K. S. Choi, K. Han, and H. W. Kim, “A Psychological Intervention Program for Patients with Breast Cancer under Chemotherapy and at a High Risk of Depression: A Randomized Clinical Trial,” Int. J. Lab. Hematol., vol. 38, no. 1, pp. 42–49, 2017.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
